Federation Des Caisses Desjardins Du Quebec Dbv Technologies S.A. Transaction History

Federation Des Caisses Desjardins Du Quebec

$17.5 Billion
Q2 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.75 - $0.95 $3,191 - $4,042	4,255 New	4,255 $3.19 Million
Q1 2022 Aug 14, 2024	BUY	$1.22 - $1.77 $5,191 - $7,531	4,255 New	4,255 $6.77 Million
Q2 2021 Aug 30, 2024	BUY	$5.32 - $6.53 $22,636 - $27,785	4,255 New	4,255 $23.2 Million
Q1 2021 Aug 30, 2024	SELL	$2.75 - $6.57 $1,498 - $3,580	-545 Reduced 11.35%	4,255 $22.7 Million
Q4 2020 Aug 30, 2024	BUY	$1.38 - $3.01 $1,380 - $3,010	1,000 Added 26.32%	4,800 $12.6 Million
Q2 2020 Aug 30, 2024	BUY	$3.74 - $6.28 $7,087 - $11,900	1,895 Added 99.48%	3,800 $16.7 Million
Q4 2019 Aug 30, 2024	BUY	$6.75 - $11.15 $2,025 - $3,345	300 Added 18.69%	1,905 $20.4 Million
Q1 2019 Aug 30, 2024	BUY	$5.81 - $9.37 $8,133 - $13,117	1,400 Added 682.93%	1,605 $12.4 Million
Q4 2018 Aug 30, 2024	BUY	$5.75 - $21.85 $1,178 - $4,479	205 New	205 $1.32 Million
Q1 2017 Aug 30, 2024	BUY	N/A	205	205 $7.22 Million

Others Institutions Holding DBVT

# of Institutions

Shares Held

253K

Call Options Held

Put Options Held

View Full List

About DBV Technologies S.A.

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $128M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

More about DBVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account